TLS

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Retrieved on: 
Tuesday, April 9, 2024

TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity.

Key Points: 
  • TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity.
  • The presentation describes the development of an investigational TLS-inducing multimodal therapeutic using the enLIGHTEN™ Discovery Platform.
  • The enLIGHTEN™ Advanced Analytics suite was applied to immune checkpoint inhibitor-treated patient datasets, and the predicted payload components included factors regulating the development of TLS.
  • “The enLIGHTEN™ Discovery Platform enables the generation of multimodal agents through the integration of artificial intelligence-driven payload combinations into programmable vectors.

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

Retrieved on: 
Monday, April 8, 2024

The poster titled “Conditionally active, therapeutic lymphotoxin beta receptor (LTBR) agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors” is being presented as part of the “Late-Breaking Research: Immunology 2” poster session (9:00 a.m. – 12:30 p.m. PT, poster section 52; board number 11).

Key Points: 
  • The poster titled “Conditionally active, therapeutic lymphotoxin beta receptor (LTBR) agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors” is being presented as part of the “Late-Breaking Research: Immunology 2” poster session (9:00 a.m. – 12:30 p.m. PT, poster section 52; board number 11).
  • The presented data demonstrate that Mestag’s bispecific antibody co-engages fibroblast activated protein (FAP) and LTBR to conditionally activate LTBR and induce Tertiary Lymphoid Structures (TLS) in the tumor.
  • In vivo data showed potent monotherapy efficacy as well as tumor regression in combination with tumor antigen or a checkpoint inhibitor.
  • Ray Jupp, PhD, Chief Scientific Officer of Mestag Therapeutics, said, “TLS is an exciting new area of anti-cancer immunology.

WatchGuard Threat Lab Analysis Shows Surge in Evasive Malware Supercharging an Already Powerful Threat Wave

Retrieved on: 
Wednesday, March 27, 2024

The average malware detections per Firebox rose 80% from the previous quarter, illustrating a substantial volume of malware threats arriving at the network perimeter.

Key Points: 
  • The average malware detections per Firebox rose 80% from the previous quarter, illustrating a substantial volume of malware threats arriving at the network perimeter.
  • Zero-day malware detections jumped to 60% of all malware detections, up from 22% the previous quarter.
  • However, zero-day malware detections with TLS fell to 61%, which was a 10% decrease from Q3, showing the unpredictability of malware in the wild.
  • Both variants redirect users to malicious links, and both malware loaders attempt to load DarkGate malware on the victim’s computer.

Telos Corporation Announces Substantial Progress on New Business Capture; Reports Fourth Quarter and Full Year 2023 Results Above Expectations

Retrieved on: 
Friday, March 15, 2024

“I am pleased to announce that Telos’ prime partners have received awards on new programs that are worth up to $525 million to Telos over a five-year period, subject to favorable resolution of protests.

Key Points: 
  • “I am pleased to announce that Telos’ prime partners have received awards on new programs that are worth up to $525 million to Telos over a five-year period, subject to favorable resolution of protests.
  • These opportunities would add high-quality revenues to the Telos portfolio, providing a path to sequential revenue growth later in 2024 and significant revenue growth in 2025,” said John B.
  • Wood, chairman and CEO.
  • “I am proud of the Telos team’s ability to manage through a challenging 2023 and deliver better than expected results across the board and I am excited about the future outlook for the Company.”

Keyfactor’s New Command SaaS Lite Solution Now Available in the Microsoft Azure Marketplace

Retrieved on: 
Thursday, April 4, 2024

Keyfactor , the identity-first security solution for modern enterprises, today announced the availability of its new lightweight certificate lifecycle management solution, Command SaaS Lite, in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure.

Key Points: 
  • Keyfactor , the identity-first security solution for modern enterprises, today announced the availability of its new lightweight certificate lifecycle management solution, Command SaaS Lite, in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure.
  • Command SaaS Lite helps organizations start their journey to visibility and take back control of their certificates.
  • Including Keyfactor Command SaaS Lite in the Microsoft Azure Marketplace equips more organizations with essential certificate management capabilities to establish and maintain digital trust.”
    Command SaaS Lite is hosted in a dedicated customer instance and managed by Keyfactor in Azure.
  • “Microsoft welcomes Command SaaS Lite to Azure Marketplace, where global customers can find, try, and buy from among thousands of partner solutions,” said Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp. “Azure Marketplace and trusted partners like Keyfactor help customers do more with less by increasing efficiency, buying confidently, and spending smarter.”
    The Azure Marketplace is an online market for buying and selling cloud solutions certified to run on Azure.

Axis Raises The Bar on Cybersecurity to Provide Wide-Ranging FIPS 140-Compliant Products to Government Customers

Retrieved on: 
Thursday, April 4, 2024

This move will improve the cybersecurity postures of Axis customers that must meet the FIPS 140 certification, specifically in the government and critical infrastructure sectors.

Key Points: 
  • This move will improve the cybersecurity postures of Axis customers that must meet the FIPS 140 certification, specifically in the government and critical infrastructure sectors.
  • By complying with the standard, Axis provides assurance to customers about the security level in Axis devices.
  • “Customers need to be confident that Axis devices ensure long-term cybersecurity and meet the latest requirements such as FIPS 140-compliance,” said Johan Paulsson, Chief Technology Officer, Axis Communications.
  • Axis’ approach to cybersecurity is to provide device protection throughout the device lifecycle, from start to beyond the point of purchase.

GoTo Takes Modern Mobile Device Management to the Next Level with Miradore Premium+

Retrieved on: 
Wednesday, April 3, 2024

GoTo , the company making IT management, support, and business communications easy, today announced the release of Miradore Premium+ .

Key Points: 
  • GoTo , the company making IT management, support, and business communications easy, today announced the release of Miradore Premium+ .
  • Premium+ is a new subscription tier for Miradore, the mobile device management (MDM) product acquired by GoTo in 2022 .
  • “Miradore Premium+ represents a significant leap forward in mobile device management.
  • Miradore Premium+ makes device management simple for IT teams with comprehensive fleet tracking and reporting, automated enrollment and configurations, enterprise-level security, and easy-to-use remote support.

BostonGene Announces Acceptance of Eight Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA.
  • BostonGene will exhibit at booth #847.
  • BostonGene, together with its collaborators, will deliver presentations on various topics, including the feasibility and utility of using comprehensive genomic and transcriptomic analysis for patients with blood and solid cancers, RNA-based models for TLS prediction in both lung and pancreatic cancers, a transcriptomic-based model to distinguish sarcomatoid features in kidney cancer and the use of comprehensive molecular profiling to evaluate the impact of race and HIV status on the genetic landscape of patients with diffuse large B-cell lymphoma (DLBCL) in southern Africa.
  • Details of BostonGene’s poster presentations at the AACR Annual Meeting are below:

Dremio Announces General Availability on Microsoft Azure

Retrieved on: 
Tuesday, March 26, 2024

Dremio , the unified lakehouse platform for self-service analytics, today announced the general availability of Dremio Cloud on Microsoft Azure.

Key Points: 
  • Dremio , the unified lakehouse platform for self-service analytics, today announced the general availability of Dremio Cloud on Microsoft Azure.
  • “With Dremio Cloud on Azure, we have the ability to shift from just standard reporting to leveraging a data set as a product.
  • "Dremio Cloud on Microsoft Azure is a game-changer for organizations seeking self-service analytics with flexibility in a SaaS environment.
  • We're thrilled to bring Dremio Cloud to Azure, enabling our customers to experience the future of data management,” said Tomer Shiran, founder and CPO of Dremio.

Polar Signals Announces Strategic Milestones: Secures $10.8M in Funding, Expands Board, and Launches AI-Driven Performance Optimizations

Retrieved on: 
Tuesday, March 12, 2024

This financial achievement reflects the strong confidence investors and, crucially, customers have in Polar Signals’ vision and mission.

Key Points: 
  • This financial achievement reflects the strong confidence investors and, crucially, customers have in Polar Signals’ vision and mission.
  • In addition to the financial boost, Polar Signals is announcing the strategic expansion of its board.
  • Polar Signals also shares that Vercel has chosen Polar Signals Cloud as their continuous profiling platform.
  • Lastly, a significant innovation from Polar Signals is the introduction of AI-driven Performance Optimizations.